PET Radiomics and Response to Immunotherapy in Lung Cancer: A Systematic Review of the Literature

Cancers, Год журнала: 2023, Номер 15(12), С. 3258 - 3258

Опубликована: Июнь 20, 2023

The aim of this review is to provide a comprehensive overview the existing literature concerning applications positron emission tomography (PET) radiomics in lung cancer patient candidates or those undergoing immunotherapy.

Язык: Английский

---

Prediction of lesion-based response to PRRT using baseline somatostatin receptor PET

Frontiers in Medicine, Год журнала: 2025, Номер 12

Опубликована: Март 14, 2025

The heterogeneous expression of somatostatin receptors in gastroenteropancreatic neuroendocrine tumors (GEP-NET) leads to significant intra-individual variability tracer uptake during pre-therapeutic [68Ga]Ga-DOTATOC PET/CT for patients receiving peptide receptor radionuclide therapy (PRRT). This study aims evaluate the lesion-based relationship between receptor-mediated and functional response PRRT. A retrospective analysis was conducted on 32 with metastatic GEP-NET (12 pancreatic 20 non-pancreatic), all treated [177Lu]Lu-octreotate (4 cycles, a mean 7.9 GBq per cycle). performed at baseline 3 months after final PRRT cycle. Tumor quantified using standardized value (SUV). For each patient, 2 well-delineated tumor lesions were selected as target lesions. SUVmax, SUVmean (automated segmentation 50% SUVmax threshold), corresponding tumor-to-liver ratios (SUVmaxT/L SUVmeanT/L) calculated. Functional assessed based relative change metabolic volume (%ΔTVPET). correlation SUV parameters analyzed Spearman's rank correlation. total 71 included analysis. 28.1 ± 15.9 13.6 5.1, respectively. Three completion, %ΔTVPET 39.6 52.1%. Baseline demonstrated poor (p = 0.706 p 0.071, respectively). In contrast, SUVmaxT/L SUVmeanT/L significantly correlated (SUVmeanT/L: 0.011, r 0.412; SUVmaxT/L: 0.004, 0.434). Among patient characteristics-including primary origin, volume, sites-only origin associated reduction (ΔTVPET%: 56.8 39.8 vs. 28.4 50.1 non-pancreatic NET; 0.020). molecular correlates pretreatment PET uptake, particularly when expressed SUVmeanT/L).

Язык: Английский

---

Comparative Evaluation of Machine Learning-Based Radiomics and Deep Learning for Breast Lesion Classification in Mammography

Diagnostics, Год журнала: 2025, Номер 15(8), С. 953 - 953

Опубликована: Апрель 9, 2025

Background: Breast cancer is the second leading cause of cancer-related mortality among women, accounting for 12% cases. Early diagnosis, based on identification radiological features, such as masses and microcalcifications in mammograms, crucial reducing rates. However, manual interpretation by radiologists complex subject to variability, emphasizing need automated diagnostic tools enhance accuracy efficiency. This study compares a radiomics workflow machine learning (ML) with deep (DL) approach classifying breast lesions benign or malignant. Methods: matRadiomics was used extract features from mammographic images 1219 patients CBIS-DDSM public database, including 581 cases 638 masses. Among ML models, linear discriminant analysis (LDA) demonstrated best performance both lesion types. External validation conducted private dataset 222 evaluate generalizability an independent cohort. Additionally, EfficientNetB6 model employed comparison. Results: The LDA achieved mean AUC 68.28% 61.53% In external validation, values 66.9% 61.5% were obtained, respectively. contrast, superior performance, achieving 81.52% 76.24% masses, highlighting potential DL improved accuracy. Conclusions: underscores limitations ML-based diagnosis. Deep proves be more effective approach, offering enhanced supporting clinicians improving patient management.

Язык: Английский

---

ChatGPT in nuclear medicine and radiology: lights and shadows in the AI bionetwork

Clinical and Translational Imaging, Год журнала: 2023, Номер 11(5), С. 407 - 411

Опубликована: Май 25, 2023

Язык: Английский

---

Nuclear Medicine and Radiological Imaging of Pancreatic Neuroendocrine Neoplasms: A Multidisciplinary Update

Journal of Clinical Medicine, Год журнала: 2022, Номер 11(22), С. 6836 - 6836

Опубликована: Ноя. 18, 2022

Pancreatic neuroendocrine neoplasms (panNENs) are part of a large family tumors arising from the system. PanNENs show low–intermediate tumor grade and generally high somatostatin receptor (SSTR) expression. Therefore, panNENs benefit functional imaging with 68Ga-somatostatin analogues (SSA) for diagnosis, staging, treatment choice in parallel morphological imaging. This narrative review aims to present conventional techniques new perspectives management panNENs, providing clinicians useful insight clinical practice. The 68Ga-SSA PET/CT is most widely used not only fr diagnosis staging purpose but also characterize biology its responsiveness SSAs. On contrary, 18F-Fluordeoxiglucose (FDG) employed systematically all panNEN patients, being preferred G2–G3, predict aggressiveness progression rate. combination 18F-FDG can finally suggest best therapeutic strategy. Other radiopharmaceuticals 68Ga-exendin-4 case insulinomas 18F-dopamine (DOPA), which be helpful SSTR-negative tumors. New promising still-under-investigation include radiolabeled SSTR antagonists 18F-SSAs. Conventional includes contrast enhanced CT multiparametric MRI. There now enriched by radiomics, non-invasive approach, very early response or progression.

Язык: Английский

---

Relationships between uptake of [68Ga]Ga-DOTA-TATE and absorbed dose in [177Lu]Lu-DOTA-TATE therapy

EJNMMI Research, Год журнала: 2022, Номер 12(1)

Опубликована: Дек. 19, 2022

Somatostatin receptor 68Ga PET imaging is standard for evaluation of a patient's suitability 177Lu peptide radionuclide therapy neuroendocrine tumours (NETs). The serves to ensure sufficient somatostatin expression, commonly evaluated qualitatively. aim this study investigate the quantitative relationships between uptake in and absorbed doses therapy. Eighteen patients underwent [68Ga]Ga-DOTA-TATE within 20 weeks prior their first cycle [177Lu]Lu-DOTA-TATE. Absorbed were estimated tumours, kidney, spleen, normal liver parenchyma using hybrid SPECT/CT-planar method. Gallium-68 activity concentrations retrieved from images also used calculate SUVs normalized SUVs, blood tissue normalization. per injected activity, compared with 1 d post-injection doses. For which there was variable number patient, both inter- intra-patient correlations analysed. Furthermore, prediction tumour based on combination tumour-specific group-based estimates effective half-lives grade 2 NETs explored. organs, only spleen showed significant correlation concentration dose (r = 0.6). significant, but moderate, obtained, respect inter-patient 0.7) 0.45) analyses. did not improve when or SUVs. relationship uptakes SPECT stronger, coefficients r 0.8 could be predicted 95% coverage interval - 65% 248%. On group level, high associated at 177Lu-DOTA-TATE therapy, has limited potential individual planning. Using SUV reference tissues do activity.

Язык: Английский

---

Radiolabeled Somatostatin Analogs for Cancer Imaging

Seminars in Nuclear Medicine, Год журнала: 2024, Номер 54(6), С. 914 - 940

Опубликована: Авг. 9, 2024

Язык: Английский

---

Performance of 18F-DCFPyL PET/CT in Primary Prostate Cancer Diagnosis, Gleason Grading and D'Amico Classification: A Radiomics-Based Study

Phenomics, Год журнала: 2023, Номер 3(6), С. 576 - 585

Опубликована: Июль 25, 2023

Язык: Английский

---

Applications of Artificial Intelligence and Radiomics in Molecular Hybrid Imaging and Theragnostics for Neuro-Endocrine Neoplasms (NENs)

Life, Год журнала: 2023, Номер 13(8), С. 1647 - 1647

Опубликована: Июль 28, 2023

Nuclear medicine has acquired a crucial role in the management of patients with neuroendocrine neoplasms (NENs) by improving accuracy diagnosis and staging as well their risk stratification personalized therapies, including radioligand therapies (RLT). Artificial intelligence (AI) radiomics can enable physicians to further improve overall efficiency use these tools both diagnostic therapeutic settings prediction tumor grade, differential from other malignancies, assessment behavior aggressiveness, treatment response. This systematic review aims describe state-of-the-art AI applications molecular imaging NENs.

Язык: Английский

---

Lutetium [177Lu]-DOTA-TATE in gastroenteropancreatic-neuroendocrine tumours: rationale, design and baseline characteristics of the Italian prospective observational (REAL-LU) study

European Journal of Nuclear Medicine and Molecular Imaging, Год журнала: 2024, Номер 51(11), С. 3417 - 3427

Опубликована: Май 22, 2024

Abstract Purpose Gastroenteropancreatic -neuroendocrine tumours (GEP-NETs) are commonly treated with surgical resection or long-term therapies for tumour growth control. Lutetium [ 177 Lu]-DOTA-TATE was approved the treatment of GEP-NETs after phase III NETTER 1trial demonstrated improved progression free survival, objective response rates and health-related quality life (HRQoL) compared to high-dose somatostatin analogues. No real-world data exist on prescribing habits clinically significant endpoints Lu]Lu-DOTA-TATE in Italy. REAL-LU is a multicentre, observational study patients unresectable/metastatic progressing standard Italian clinical practice. A pre-specified interim analysis performed at end enrolment period, from which described herein. Methods Overall duration will be approximately 48 months, 12- 36-month recruitment follow-up periods, respectively. The primary evaluate effectiveness terms progression-free survival. Secondary objectives include safety, impact HRQoL, identification prognostic factors. This describes patient profiles, enrollment, those prescribed Results Among 161 evaluable patients, mean age 64.7 ± 10.3 years entry, 83.8% presented no signs disease physical examination, most had minor symptoms. All metastatic disease, liver (83.9%) median two sites. In 90.7% stage IV, 68.3% ≥ 1 target lesion. mainly as second-line therapy (61.6%) following surgery (58.4%). HRQoL assessments revealed high levels functioning low symptoms baseline; 50.0% were symptom-free entry. Conclusion characteristics who received [177Lu]Lu-DOTA-TATE Italy similar GEP-NET population trial but higher proportion grade 2 (71%). With regard tumor profile, our cohort appears closer that NETTER-2 included G2 G3 advanced (i.e. Ki-67 10% ≤ 55%). Further safety can anticipated mature. Study Registration: ClinicalTrials.gov, NCT04727723; Registration Date: 25 January, 2021; https://clinicaltrials.gov/study/NCT04727723?cond=NCT04727723&rank=1

Язык: Английский

---